A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2006

Conditions
Irritable Bowel Syndrome (IBS)
Interventions
DRUG

GW427353

DRUG

Placebo

Trial Locations (19)

2139

GSK Investigational Site, Concord

3128

GSK Investigational Site, Box Hill

3144

GSK Investigational Site, Malvern

4000

GSK Investigational Site, Spring Hill

4021

GSK Investigational Site, Kippa-Ring

4510

GSK Investigational Site, Caboolture

5000

GSK Investigational Site, Adelaide

10629

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

13125

GSK Investigational Site, Berlin

20249

GSK Investigational Site, Hamburg

22143

GSK Investigational Site, Hamburg

58455

GSK Investigational Site, Witten

59000

GSK Investigational Site, Lille

63500

GSK Investigational Site, Issoire

85100

GSK Investigational Site, Les Sables-d'Olonne

94400

GSK Investigational Site, Vitry-sur-Seine

02100

GSK Investigational Site, Saint-Quentin

04109

GSK Investigational Site, Leipzg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY